[96a5a0]: / output / allTrials / identified / NCT05656573_identified.json

Download this file

668 lines (668 with data), 29.0 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
{
"info": {
"nct_id": "NCT05656573",
"official_title": "Phase I Study of CART-PSMA Cells in Patients With Advanced Prostate Cancer",
"inclusion_criteria": "1. All participants must have the ability to understand and the willingness to sign a written informed consent.\n2. Histologic confirmation of prostate cancer.\n3. Tumor expressing PSMA as demonstrated by immunohistochemistry analysis or other methods.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.\n5. Under general air conditions, blood oxygen saturation >90%.\n6. Adequate liver function, specifically alanine aminotransferase (ALT) < 3 times of upper limit of normal (ULN), aspartate transferase (AST)< 3 times of ULN, serum bilirubin and alkaline phosphatase < 2 times of ULN.\n7. Adequate renal function, specifically serum creatinine < 2.0 mg/dl.\n8. Adequate cardiac function, specifically left ventricular ejection fraction (LVEF)≥50%.\n9. Hemoglobin concentration ≥80g/L.\n10. The side effects brought by the latest treatment should be recovered, and the latest chemotherapy should be at least 7 days before; At least three t½ have passed since the latest immunotherapy.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 35 Years\nMust have maximum age of 85 Years",
"exclusion_criteria": "1. Patients with other malignant tumors or major diseases.\n2. Patients who are already undergoing other clinical drug trials or other gene therapy or cell therapy.\n3. Patients with uncontrolled active infection.\n4. Patients with active hepatitis B or hepatitis C infection.\n5. Patients with human immunodeficiency virus (HIV) infection.\n6. Patients who are being treated with immunosuppressive agents or systemic steroids (other than inhalation therapy).\n7. Patients with various types of serious heart disease or a history of severe cerebrovascular disease.\n8. Patients with congenital immune deficiency diseases or bone marrow deficiency diseases.\n9. Patients with active autoimmune disease, including connective tissue disease, uveitis, inflammatory bowel disease, or multiple sclerosis; or a history of severe (as judged by the physician-investigator) autoimmune disease requiring prolonged immunosuppressive therapy.\n10. Patients with active medical condition that, in the opinion of the physician-investigator, would substantially increase the risk of uncontrollable CRS (cytokine release syndrome) or CAR Neurotoxicity.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. All participants must have the ability to understand and the willingness to sign a written informed consent.",
"criterions": [
{
"exact_snippets": "ability to understand",
"criterion": "cognitive ability",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "willingness to sign a written informed consent",
"criterion": "willingness to consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "2. Histologic confirmation of prostate cancer.",
"criterions": [
{
"exact_snippets": "Histologic confirmation of prostate cancer",
"criterion": "prostate cancer",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "histologic"
}
]
}
]
},
{
"line": "3. Tumor expressing PSMA as demonstrated by immunohistochemistry analysis or other methods.",
"criterions": [
{
"exact_snippets": "Tumor expressing PSMA",
"criterion": "PSMA expression in tumor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "as demonstrated by immunohistochemistry analysis or other methods",
"criterion": "method of PSMA expression demonstration",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"immunohistochemistry analysis",
"other methods"
]
}
]
}
]
},
{
"line": "4. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "5. Under general air conditions, blood oxygen saturation >90%.",
"criterions": [
{
"exact_snippets": "blood oxygen saturation >90%",
"criterion": "blood oxygen saturation",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 90,
"unit": "%"
}
}
]
}
]
},
{
"line": "6. Adequate liver function, specifically alanine aminotransferase (ALT) < 3 times of upper limit of normal (ULN), aspartate transferase (AST)< 3 times of ULN, serum bilirubin and alkaline phosphatase < 2 times of ULN.",
"criterions": [
{
"exact_snippets": "alanine aminotransferase (ALT) < 3 times of upper limit of normal (ULN)",
"criterion": "alanine aminotransferase (ALT)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "times of ULN"
}
}
]
},
{
"exact_snippets": "aspartate transferase (AST)< 3 times of ULN",
"criterion": "aspartate transferase (AST)",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 3,
"unit": "times of ULN"
}
}
]
},
{
"exact_snippets": "serum bilirubin ... < 2 times of ULN",
"criterion": "serum bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "times of ULN"
}
}
]
},
{
"exact_snippets": "alkaline phosphatase < 2 times of ULN",
"criterion": "alkaline phosphatase",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "times of ULN"
}
}
]
}
]
},
{
"line": "7. Adequate renal function, specifically serum creatinine < 2.0 mg/dl.",
"criterions": [
{
"exact_snippets": "Adequate renal function",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "serum creatinine < 2.0 mg/dl",
"criterion": "serum creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 2.0,
"unit": "mg/dl"
}
}
]
}
]
},
{
"line": "8. Adequate cardiac function, specifically left ventricular ejection fraction (LVEF)≥50%.",
"criterions": [
{
"exact_snippets": "Adequate cardiac function, specifically left ventricular ejection fraction (LVEF)≥50%.",
"criterion": "left ventricular ejection fraction (LVEF)",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
},
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "%"
}
}
]
}
]
},
{
"line": "9. Hemoglobin concentration ≥80g/L.",
"criterions": [
{
"exact_snippets": "Hemoglobin concentration ≥80g/L",
"criterion": "hemoglobin concentration",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 80,
"unit": "g/L"
}
}
]
}
]
},
{
"line": "10. The side effects brought by the latest treatment should be recovered, and the latest chemotherapy should be at least 7 days before; At least three t½ have passed since the latest immunotherapy.",
"criterions": [
{
"exact_snippets": "The side effects brought by the latest treatment should be recovered",
"criterion": "side effects from latest treatment",
"requirements": [
{
"requirement_type": "recovery",
"expected_value": true
}
]
},
{
"exact_snippets": "the latest chemotherapy should be at least 7 days before",
"criterion": "latest chemotherapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": ">=",
"value": 7,
"unit": "days"
}
}
]
},
{
"exact_snippets": "At least three t½ have passed since the latest immunotherapy",
"criterion": "latest immunotherapy",
"requirements": [
{
"requirement_type": "time since treatment",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "t½"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "Must be MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
},
{
"line": "Must have minimum age of 35 Years",
"criterions": [
{
"exact_snippets": "minimum age of 35 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 35,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 85 Years",
"criterions": [
{
"exact_snippets": "maximum age of 85 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 85,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Patients with other malignant tumors or major diseases.",
"criterions": [
{
"exact_snippets": "Patients with other malignant tumors",
"criterion": "other malignant tumors",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients with ... major diseases",
"criterion": "major diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "3. Patients with uncontrolled active infection.",
"criterions": [
{
"exact_snippets": "uncontrolled active infection",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "uncontrolled"
}
]
}
]
},
{
"line": "5. Patients with human immunodeficiency virus (HIV) infection.",
"criterions": [
{
"exact_snippets": "Patients with human immunodeficiency virus (HIV) infection.",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "6. Patients who are being treated with immunosuppressive agents or systemic steroids (other than inhalation therapy).",
"criterions": [
{
"exact_snippets": "Patients who are being treated with immunosuppressive agents",
"criterion": "treatment with immunosuppressive agents",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients who are being treated with ... systemic steroids (other than inhalation therapy)",
"criterion": "treatment with systemic steroids",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "exclusion",
"expected_value": "inhalation therapy"
}
]
}
]
},
{
"line": "7. Patients with various types of serious heart disease or a history of severe cerebrovascular disease.",
"criterions": [
{
"exact_snippets": "serious heart disease",
"criterion": "heart disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "serious"
}
]
},
{
"exact_snippets": "history of severe cerebrovascular disease",
"criterion": "cerebrovascular disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
},
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "8. Patients with congenital immune deficiency diseases or bone marrow deficiency diseases.",
"criterions": [
{
"exact_snippets": "Patients with congenital immune deficiency diseases",
"criterion": "congenital immune deficiency diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "bone marrow deficiency diseases",
"criterion": "bone marrow deficiency diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "9. Patients with active autoimmune disease, including connective tissue disease, uveitis, inflammatory bowel disease, or multiple sclerosis; or a history of severe (as judged by the physician-investigator) autoimmune disease requiring prolonged immunosuppressive therapy.",
"criterions": [
{
"exact_snippets": "Patients with active autoimmune disease",
"criterion": "active autoimmune disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "including connective tissue disease",
"criterion": "connective tissue disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "uveitis",
"criterion": "uveitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "inflammatory bowel disease",
"criterion": "inflammatory bowel disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "multiple sclerosis",
"criterion": "multiple sclerosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "history of severe (as judged by the physician-investigator) autoimmune disease requiring prolonged immunosuppressive therapy",
"criterion": "history of severe autoimmune disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
},
{
"requirement_type": "treatment",
"expected_value": "prolonged immunosuppressive therapy"
}
]
}
]
},
{
"line": "10. Patients with active medical condition that, in the opinion of the physician-investigator, would substantially increase the risk of uncontrollable CRS (cytokine release syndrome) or CAR Neurotoxicity.",
"criterions": [
{
"exact_snippets": "active medical condition ... would substantially increase the risk of uncontrollable CRS (cytokine release syndrome)",
"criterion": "active medical condition",
"requirements": [
{
"requirement_type": "risk increase",
"expected_value": "substantially increase the risk of uncontrollable CRS (cytokine release syndrome)"
}
]
},
{
"exact_snippets": "active medical condition ... would substantially increase the risk of ... CAR Neurotoxicity",
"criterion": "active medical condition",
"requirements": [
{
"requirement_type": "risk increase",
"expected_value": "substantially increase the risk of CAR Neurotoxicity"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "2. Patients who are already undergoing other clinical drug trials or other gene therapy or cell therapy.",
"criterions": [
{
"exact_snippets": "Patients who are already undergoing other clinical drug trials",
"criterion": "participation in other clinical drug trials",
"requirements": [
{
"requirement_type": "participation",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients who are already undergoing other gene therapy",
"criterion": "participation in other gene therapy",
"requirements": [
{
"requirement_type": "participation",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients who are already undergoing other ... cell therapy",
"criterion": "participation in other cell therapy",
"requirements": [
{
"requirement_type": "participation",
"expected_value": true
}
]
}
]
},
{
"line": "4. Patients with active hepatitis B or hepatitis C infection.",
"criterions": [
{
"exact_snippets": "active hepatitis B",
"criterion": "hepatitis B infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "active hepatitis C",
"criterion": "hepatitis C infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"failed_miscellaneous": []
}